Filtered By:
Condition: Hemorrhagic Stroke
Drug: Warfarin

This page shows you your search results in order of date. This is page number 17.

Order by Relevance | Date

Total 721 results found since Jan 2013.

Left atrial appendage closure: a therapy uniquely suited for specific populations of patients with atrial fibrillation
This article is protected by copyright. All rights reserved.
Source: Journal of Cardiovascular Electrophysiology - September 12, 2019 Category: Cardiology Authors: Eric Black ‐Maier, Jonathan P. Piccini, Christopher Granger Tags: POINT OF VIEW Source Type: research

Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease: A Meta-Analysis and Systematic Review
ConclusionsBased on current publications, the use of NOACs is at least non-inferior to warfarin in patients with AF and liver disease.
Source: American Journal of Cardiovascular Drugs - September 3, 2019 Category: Cardiology Source Type: research

A comparison of post ‐procedural anticoagulation in high‐risk patients undergoing WATCHMAN device implantation
ConclusionFor patients with Atrial Fibrillation at high risk of both thromboembolic and hemorrhagic events, NOACs as compared to Warfarin, are seem to be safe and effective for short ‐term anticoagulation following LAAC with the WATCHMAN Device. Further validation in large randomized controlled trials is required.This article is protected by copyright. All rights reserved
Source: Pacing and Clinical Electrophysiology : PACE - September 2, 2019 Category: Cardiology Authors: Joshua A. Cohen, E. Kevin Heist, Jennifer Galvin, Hang Lee, Matthew Johnson, Michael Fitzsimons, Kathryn Slattery, Brian Ghoshhajra, Rahul Sakhuja, Grace Ha, Margaux Forsch, Linsheng Shi, Jacqueline Danik, Jacob Dal ‐Bianco, Danita Sanborn Tags: ELECTROPHYSIOLOGY Source Type: research

Outcomes of direct oral anticoagulant- and warfarin-associated hemorrhage: A single center retrospective cohort study
Direct oral anticoagulants (DOACs) are now a mainstay of anticoagulant therapy for the prevention and treatment of venous thromboembolism (VTE) and stroke prevention in non-valvular atrial fibrillation (a-fib). However, bleeding-related morbidity and mortality remains a feared complication. Bleeding in patients taking DOACs in clinical trials showed comparable, if not more favorable, outcomes compared to that of warfarin [1 –4]. However, the safety of DOAC use should also be evaluated in less selected cohorts in the real-world.
Source: Thrombosis Research - September 2, 2019 Category: Hematology Authors: Lorraine Cafuir, En Cheng, Christine Kempton Tags: Letter to the Editors-in-Chief Source Type: research

Does X(a) mark the spot? An indirect mixed treatment comparison of Xa inhibitors compared to warfarin for patients with Atrial Fibrillation
ConclusionsThe Non-vitamin K antagonist oral anticoagulants constitute a new and promising category in the field of atrial fibrillation, even in the context of uncertainty, which an indirect comparison yields.
Source: Health Policy and Technology - August 10, 2019 Category: Health Management Source Type: research

Perioperative Management of the Direct-Acting Oral Anticoagulants.
Abstract Since the 1950s, warfarin has been the most commonly prescribed anticoagulant in the prevention of stroke-related thromboembolism. Beginning in 2008, direct-acting oral anticoagulants (DOACs) began to replace warfarin. Although the DOACs had a greater safety profile, approved reversal agentsfor use in emergent/excessive hemorrhage did not exist. This course reviews the perioperative management of the DOACs. PMID: 31587718 [PubMed - in process]
Source: AANA Journal - July 31, 2019 Category: Anesthesiology Authors: Kane TD, Tubog TD Tags: AANA J Source Type: research

Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption
Conclusion Antiplatelet or vitamin K antagonist suspension has a temporal relationship with the occurrence of stroke and TIA. Since these events are preventable, it is crucial that healthcare professionals convince their patients that drug withdrawal can cause serious consequences.RESUMO Pacientes em terapia anticoagulante ou antiagregante plaquet ária frequentemente são solicitados a descontinuar essas medicações antes e durante procedimentos cirúrgicos ou invasivos. Se o paciente interromper tratamento sem supervisão médica, poderá aumentar de risco de acidente vascular cerebral (AVC). Objetivo Identificar preval...
Source: Arquivos de Neuro-Psiquiatria - July 29, 2019 Category: Neurology Source Type: research

Reversal and Resumption of Antithrombotic Therapy in LVAD-Associated Intracranial Hemorrhage
ConclusionsReversal of anticoagulation appears safe after LVAD-associated intracranial hemorrhage, though inadequate reversal was common. Resumption of warfarin ± antiplatelet was associated with fewer fatal and nonfatal thrombotic events compared with antiplatelets alone, though more nonfatal hemorrhage events occurred.
Source: The Annals of Thoracic Surgery - June 20, 2019 Category: Cardiovascular & Thoracic Surgery Source Type: research

Warfarin in nonvalvular atrial fibrillation-Time for a change?
Abstract Warfarin is the most commonly prescribed anticoagulant in hemodialysis (HD) patients with nonvalvular atrial fibrillation (NVAF). Recent trends show that Nephrologists are increasingly prescribing novel oral anticoagulants, despite the fact that no randomized clinical trials have been conducted in dialysis patients. Difficulties maintaining international normalized ratio in the therapeutic range, increased risk of intracranial hemorrhage and concerns regarding warfarin-induced vascular calcification and calciphylaxis may be responsible. Anticoagulation quality is poor in HD patients. A variety of factors ...
Source: Seminars in Dialysis - June 16, 2019 Category: Urology & Nephrology Authors: Reilly RF, Jain N Tags: Semin Dial Source Type: research

Determinants of Antithrombotic Treatment for Atrial Fibrillation in Octogenarians: Results of the OCTOFA Study
ConclusionsMost private-practice cardiologists prescribe anticoagulant treatment according to current guidelines in elderly atrial fibrillation patients. Non-vitamin K antagonist oral anticoagulants represent a significant proportion of prescriptions.
Source: Clinical Drug Investigation - June 9, 2019 Category: Drugs & Pharmacology Source Type: research

Optimal Choice of Pharmacological Therapy – Prevention of Stroke and Assessment of Bleeding Risk in Patients with Atrial Fibrillation
Conclusions:Novel oral anticoagulants (NOACs) seem to be a better choice as a pharmacological therapy in the treatment of AF, due to a lack of adequate monitoring of patients ’ international normalized ratio (INR) values. CHA2DS2‑VASc and HASBLED scores must be used as a part of routine clinical diagnostics when dealing with patients with AF.Keywords:Atrial fbrillation, hemorrhage, risk, stroke, therapeutics
Source: International Journal of Preventive Medicine - June 3, 2019 Category: International Medicine & Public Health Source Type: research

Comparison of the New Oral Anticoagulants and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Systematic Review and Meta-Analysis
ConclusionsThe efficacy and safety of NOACs as thromboprophylaxis for AF and VHD are similar to those of warfarin.
Source: Drugs in R&D - May 3, 2019 Category: Drugs & Pharmacology Source Type: research

Strategies for Reversal of Warfarin Following Acute Bleed
A patient with altered mental status presents via EMS after being found by family. She has a medical history significant for hypertension, diabetes, and atrial fibrillation for which she receives oral anticoagulation for stroke prevention. After the initial workup comes back negative, a computed tomographic scan of the brain is performed and the patient is found to have a large intraparenchymal hemorrhage that extends into the ventricles.
Source: Journal of Emergency Nursing: JEN - April 30, 2019 Category: Nursing Authors: Brian W. Gilbert, Tessa Reynolds, Joel B. Huffman, Katherine Hall Tags: Pharm/Tox Corner Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Effect of Warfarin on Ischemic Stroke, Bleeding, and Mortality in Patients with Atrial Fibrillation Receiving Peritoneal Dialysis
ConclusionThere is no significant association between warfarin treatment with risks of mortality, ischemic stroke or bleeding in patients with atrial fibrillation receiving peritoneal dialysis.
Source: American Journal of Cardiovascular Drugs - April 22, 2019 Category: Cardiology Source Type: research